<DOC>
	<DOCNO>NCT02215252</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety PF-05089771 monotherapy add-on pregabalin treatment painful diabetic peripheral neuropathy ( DPN )</brief_summary>
	<brief_title>A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin ( Lyrica ) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy ( DPN )</brief_title>
	<detailed_description />
	<mesh_term>Pain</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Men woman age 18 year 80 year . Diagnosis Type 2 diabetes mellitlus ( T2DM ) current glycosylated hemoglobin A1c ( HbA1c ) level â‰¤ 11 % Screening stable antidiabetic medication regimen least 30 day prior randomization . Presence ongoing pain due DPN least 6 month . Willing discontinue protocolspecified prohibit pain medication DPN throughout duration study . Painful neuropathy painful condition DPN may confound evaluation pain due DPN study . Subjects fail previously pregabalin ( recommended label dose adequate duration ) due lack efficacy . Subjects clinically significant medical psychiatric condition clinically significant laboratory test abnormality . Pregnant woman , lactate mother , men partner currently pregnant , woman suspect pregnant , woman wish pregnant course clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>